At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EQ Equillium Inc.
Trading 07-06 15:30:53 EDT
2.80
-0.11
-3.78%
High3.00Low2.80Vol678.86K
Open2.90D1 Closing2.91Amplitude6.87%
Mkt Cap177.03MTradable Cap99.22MTotal Shares63.23M
T/O1.98MT/O Rate1.92%Tradable Shares35.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

EQ Resources Issues New Shares and Signals Ongoing Growth Strategy in Tungsten
TIPRANKS  ·  07-06 10:07
EQ Resources Issues New Shares and Signals Ongoing Growth Strategy in Tungsten
EQ Resources Seeks ASX Quotation for New Share Issue
TIPRANKS  ·  07-06 09:57
EQ Resources Seeks ASX Quotation for New Share Issue
Investor Outlook: EQ Bank begins PC Financial integration after acquisition
Bloomberg  ·  07-03
Investor Outlook: EQ Bank begins PC Financial integration after acquisition
EQ Resources (ASX:EQR) Is Up 17.3% After Critical Minerals Interest Surges Around Tungsten Supply Security
Simply Wall St.  ·  07-03
EQ Resources (ASX:EQR) Is Up 17.3% After Critical Minerals Interest Surges Around Tungsten Supply Security
Equillium (EQ) Gets a Buy from Oppenheimer
TIPRANKS  ·  06-30
Equillium (EQ) Gets a Buy from Oppenheimer
EQ Resources Issues New Shares and Pursues Expansion Around Mt Carbine
TIPRANKS  ·  06-30
EQ Resources Issues New Shares and Pursues Expansion Around Mt Carbine
EQ Resources Updates Market on Cessation of Listed Options
TIPRANKS  ·  06-30
EQ Resources Updates Market on Cessation of Listed Options
EQ Resources Seeks ASX Quotation for Newly Issued Shares
TIPRANKS  ·  06-30
EQ Resources Seeks ASX Quotation for Newly Issued Shares
Press Release: Next Bridge Hydrocarbons Answers Frequently Asked Questions Regarding the Upcoming Special Dividend of Common Stock
Dow Jones  ·  06-30
Press Release: Next Bridge Hydrocarbons Answers Frequently Asked Questions Regarding the Upcoming Special Dividend of Common Stock
Elmet Lifts Stake in EQ Resources to Bolster Western Tungsten Supply Chain
TIPRANKS  ·  06-26
Elmet Lifts Stake in EQ Resources to Bolster Western Tungsten Supply Chain
Elmet exercises option to purchase 20M shares of EQ Resources
TIPRANKS  ·  06-26
Elmet exercises option to purchase 20M shares of EQ Resources
The Elmet Group Co. Increases Ownership in EQ Resources Limited, Furthering its Investment in Critical Tungsten Supply Chain
GlobeNewswire  ·  06-26
The Elmet Group Co. Increases Ownership in EQ Resources Limited, Furthering its Investment in Critical Tungsten Supply Chain
EQ Resources Issues New Shares After Option Exercise, Confirms Regulatory Compliance
TIPRANKS  ·  06-24
EQ Resources Issues New Shares After Option Exercise, Confirms Regulatory Compliance
EQ Resources Seeks ASX Quotation for Additional 300,000 Shares
TIPRANKS  ·  06-24
EQ Resources Seeks ASX Quotation for Additional 300,000 Shares
EQ Resources Issues New Shares via Option Exercises and Confirms Regulatory Compliance
TIPRANKS  ·  06-23
EQ Resources Issues New Shares via Option Exercises and Confirms Regulatory Compliance
EQ Resources Seeks ASX Quotation for 1.5 Million New Shares
TIPRANKS  ·  06-23
EQ Resources Seeks ASX Quotation for 1.5 Million New Shares
EQ Resources (ASX:EQR) Shares Could Be 16% Overvalued After Mine Access Progress
Simply Wall St.  ·  06-23
EQ Resources (ASX:EQR) Shares Could Be 16% Overvalued After Mine Access Progress
EQ Resources Begins Phase 1 Drilling Program at Spain Tungsten Mine
MT Newswires Live  ·  06-19
EQ Resources Begins Phase 1 Drilling Program at Spain Tungsten Mine
Canaccord Genuity Sticks to Its Buy Rating for EQ Resources Limited (EQR)
TIPRANKS  ·  06-19
Canaccord Genuity Sticks to Its Buy Rating for EQ Resources Limited (EQR)
23% Of This Equillium Insider's Holdings Were Sold
Simply Wall St.  ·  06-18
23% Of This Equillium Insider's Holdings Were Sold

Introduction

Company Name.
Equillium Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Issue price:
--